Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

Phase II trial to study the effectiveness of broxuridine in treating patients who are undergoing surgery for stage I or stage II prostate cancer. Broxuridine may help doctors determine the rate of growth of prostate tumors and help them plan effective treatment

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: 5-bromouridine; Bromodeoxyuridine

Criteria

Inclusion Criteria:

• Diagnosis of stage I or II (T1-2) carcinoma of the prostate

• PSA greater than 8 ng/mL

• Abnormal findings on digital rectal examination

• Eligible for radical prostatectomy

• Performance status - ECOG 0 or 1

• No prior biologic therapy

• No prior chemotherapy

• No prior neoadjuvant hormonal therapy

• No prior radiotherapy

• See Disease Characteristics

• No prior therapy that would affect tumor growth rates or volume